Cortice Biosciences Announces Presentation of Results from Placebo-Controlled Phase 1 Clinical Trials Evaluating TPI 287 for Treatment of Alzheimer’s Disease and Related Tauopathies

Cortice Biosciences Announces Presentation of Results from Placebo-Controlled Phase 1 Clinical Trials Evaluating TPI 287 for Treatment of Alzheimer’s Disease and Related Tauopathies

Possible evidence of clinical activity in Alzheimer’s disease patients treated with TPI 287 Drug administration was generally well-tolerated Results support further exploration of TPI 287 for treatment of neurodegenerative diseases Source: Cortice Biosciences, Inc....